Search

Displaying results 9421 - 9430 of 10000 in total
  1. Drug

    PHA-767491

    go.drugbank.com/drugs/DB17043
    Investigational

    PHA-767491 is a Cdc7/CDK9 inhibitor.[A253077]

  2. Drug

    Pristimerin

    go.drugbank.com/drugs/DB17049
    Experimental

    Pristimerin is a quinone methide triterpenoid researched for its anti-cancer potential.[A253107]

  3. Drug

    TPCA-1

    go.drugbank.com/drugs/DB17058
    Experimental

    TPCA-1 is a selective inhibitor of human IκB kinase 2 (IKK-2).[A253152]

  4. Drug

    Sepantronium

    go.drugbank.com/drugs/DB17062
    Investigational

    Sepantronium is a compound that suppresses survivin expression in a dose and time-dependent manner, and causes broad-range apoptosis.[A253167]

  5. Drug

    JNJ-17216498

    go.drugbank.com/drugs/DB17087
    Investigational

    JNJ-17216498 is a histamine receptor H3 antagonist developed by Johnson and Johnson for the treatment of narcolepsy.[A253997]

  6. Drug

    KT-333

    go.drugbank.com/drugs/DB17165
    Investigational

    KT-333 is a small molecule targeted protein degrader of STAT3.[L44086]

  7. Drug

    Diaziquone

    go.drugbank.com/drugs/DB17174
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    OS2966

    go.drugbank.com/drugs/DB17207
    Investigational

    OS2966 is a humanized integrin β1 (CD29) blocking antibody currently evaluated for the treatment of acute myeloid leukemia, glioblastoma and ovarian cancer.[A254561, L47351]

  9. Drug

    PRGN-3006

    go.drugbank.com/drugs/DB17229
    Investigational

    PRGN-3006 are autologous CD3+ T cells genetically modified using a non-viral system to express a CD33 CAR, membrane-bound interleukin-15, and a truncated form of human HER1T (kill switch) on the cell surface

    Synonyms: Autologous CD3+ T cells genetically modified using a non-viral system to express a CD33 CAR, membrane bound Interleukin-15, and a truncated form of human HER1t (kill switch) on the cell surface
  10. Drug

    ST-36

    go.drugbank.com/drugs/DB17275
    Experimental

    ST-36 is a cell-penetrating dominant-negative form of activating transcription factor 5. In 2017, it received orphan drug designation by the FDA for the treatment of glioma.[L47341]